Thank you for submitting your manuscript for consideration by The EMBO Journal. Your manuscript has been evaluated by two referees and I enclose their reports below. Overall they find that the manuscript provides important information regarding the PABPC1 interactions with human and Drosophila GW182 proteins. However, they do provide mixed recommendations with referee #1 more positive than referee #2, from their reports it is clear that further experiments are required for the manuscript to be further considered for The EMBO Journal. Referee #2 raises a number of concerns regarding the interpretation of certain experiments, which need to be experimentally strengthened. This is important because currently s/he does not strongly support publication in the EMBO Journal. Given interest in the study should you be able to address these issues, we would be wiling to consider a revised manuscript.
I should remind you that it is EMBO Journal policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript. When you submit a revised version to the EMBO Journal, please make sure you upload a letter of response to the referees' comments. Please note that when preparing your letter of response to the referees' comments that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal ------------------------------------------------REFEREE COMMENTS Referee #1 (Remarks to the Author):
Previous studies have shown that the C-terminal portion of the human TNRC6C protein and its Drosophila melanogaster (Dm) homolog GW182 mediate post-transcriptional repression by miRNAs and that their affinity for the poly(A) binding protein PABPC1 is important for this effect. However, there appeared to be a discrepancy in how PABPC1 binds to TNRC6C and Dm GW182, with TNRC6C relying on the interaction of its conserved PAM2 motif with the MLLE domain of PABPC1 and Dm GW182 relying instead on the interaction of two distinct elements (M2 + C-term) with the RRM domains of PABPC1. The present manuscript clarifies this discrepancy by presenting persuasive evidence, based on co-immunoprecipitation experiments, that both of these means are used by the human TNRC6 proteins and by Dm GW182 to interact with PABPC1. Nevertheless, there can be significant differences in the relative contribution of each type of interaction to the overall binding affinity, most notably the very small contribution of PAM2 to PABPC1 binding by Dm GW182. The authors further show that there is a good correlation between the effect of TNRC6/GW182 mutations on PABPC1 binding and on gene silencing in Drosophila and human cells, even for mRNAs that lack a poly(A) tail. These results should help to bring some unity to models advanced to explain the mechanism(s) by which miRNAs downregulate gene expression.
Additional comment:
In the next to last sentence of page 11, the authors describe the level of expression of the various Dm GW182 mutants in S2 cells as "equivalent". However, the concentrations of these proteins appear to differ by as much as 3-4 fold, as judged by visual examination of the western blot in Figure 4H . The wording of this sentence should be changed, and the bar graph data in the other panels of Figure 4 should be adjusted to reflect the relative concentration of each mutant.
Referee #2 (Remarks to the Author):
The study by Huntzinger and al. examines domain interactions between GW182 and the PABPC proteins from fly and TNRC6-PABPC from human. The authors claim to have identified a critical amino acid for the function of GW182 proteins that leads to loss of binding to PABPC when substituted. Generally, this study demonstrates evolutionarily conserved interactions and function of GW182 and the PABPC proteins in miRNA-targeted gene silencing which is mediated by different protein subdomains in fly compared to human cells. These are important observations and could contribute to our understanding of the importance of the GW182-PABPC interaction. However, some observations have been previously published by this group and other data support more than one conclusion which may not be the same as the conclusion reached by these authors.
Concerns that need to be clarified: 1) A major claim of this paper is that the interaction between Dm GW182 and PABPC1 is mediated by the combination of M2 and the C-terminus but not the PAM2 domain. However, the M2 deletion alone does not contribute to the PABPC1 interaction any more than the PAM2 deletion (Fig. 2C lanes 11 & 12) and does not significantly reduce silencing any more than the PAM2 deletion (Fig. 4D & F) . In contrast, the M2 deletion does not significantly decrease the interaction with PABPC1 more than the C-terminal deletion alone ( Fig. 2 lanes 13 & 14) and does not contribute to silencing any more than the C-terminal deletion alone (Fig. 4B & D & F) . By these data the M2 does not contribute either to the PABC1 interaction or the function in silencing. Should the major claim of this paper be that the interaction between Dm GW182 and PABPC1 is mediated by the C-terminus but not M2 or the PAM2 domain? Also, to claim an effect of PAM2 in GW182 in the context of other mutations the authors would also need to assess the PAM2 deletion in the context of the Cterminal deletion without the M2 deletion.
2) It is clear that the PAM2 domain is not required for GW182 interaction with PABPC1 or gene silencing because the inactivating phenylalanine mutations does not reduce the PABC1 interaction ( Fig. 3 lanes 11 & 12) and is able to rescue silencing (Fig. 5B & D & F) . These are important observations. Still, it is not clear why the PAM2 deletion increases the effect of the C-terminal deletion (Fig. 4B & D & F) . Can the authors demonstrate (or speculate?) why the full effect of the C-terminal deletion (almost to the level of the silencing domain deletion) is observed only it is combined with the PAM2 deletion ( Fig. 4D & F) ?
Claims not supported by the data:
1) The authors state (p.18) that: "The differences between species in the requirements for PABPC1-binding can be attributed to the GW182 proteins and not to PABPC1 because human TNRC6s interact in a similar manner with both human and Dm PABPC1 (Figures 2 and 3 )." However, differences are clearly detected when comparing the binding ability of deleted M2 and C terminal TNRC6s mutants in insect S2 versus human Hek293 cells. Whereas the M2 or C terminal deletions in TNRC6B slightly increase the affinity for Dm PABPC, the homologous deletions in TNRC6C dramatically decreases the interaction with human PABPC (compare lanes 11 and 12 in Fig. 2B to lanes 12 and 14 in Fig. 3E ). What could be the explanation for the observed differences? In addition, is the TNRC6 double mutant lacking both M2 and C terminal still able to interact with human PABC in Hek cells?
2) Fig. 7 is not convincing and the claim that GW182 -PABPC interaction is required for silencing of unadenylated reporters is not supported by experimental evidence. The authors would have to demonstrate that PABPC coimmunoprecipitates with GW182 protein when pulling down unadelylated target mRNAs to support this claim. Also, is this phenomenon particular to Dm cells or is it observed in human cells? Although it is presumed that GW182 proteins bind PABPC, it is known that other proteins mediate binding via PABPC domains, as is the case for EDD E3 ubiquitin ligase implicated in degradation of protein targets via ubiquitination.
3) Fig. 8 is not convincing and there are multiple interpretations for this data. There are several proteins with PAM2 domains. The PAM2 motif of Paip1 and MLLE domain of PABC are known to serve as scaffolds for interaction with various protein factors. Overexpressing either of these domains could increase interaction with proteins other than TNRC6s and could affect processes other than microRNA mediated silencing. An indirect effect on the microRNA targeted reporter is suggested by the modest effect observed when PAM2 motif of Paip1 and MLLE domain of PABC are overexpressed. This data should be removed from the manuscript or more direct evidence is required to support the claim that the interaction of TNRC6s with PABPC1 contributes to silencing in human cells.
Minor concern:
1) The figure legends are cryptic and difficult to follow. The authors should describe the experiments more clearly and completely in the legends.
Previously published observations:
1) On page 8, last paragraph Huntzinger and al. state that: " In the context of full length Dm GW182, deleting the PAM2 motif has little to no effect (Fig. 2C , lane 11); however, PABPC1 will not bind to Dm GW182 if in addition to the PAM2 motif, the M2 and C-term regions are deleted ( Figure 2C , lane 15). A similar effect is observed when the entire silencing domain is deleted (Figure2C, lane 16; and Zekri et al, 2009 ). An important implication of these results is that, in addition to the M2 and C-term regions, the PAM2 motif of GW182 contributes to PABPC1-binding, although on its own this motif is not sufficient." "...To define which sequences within the middle region contribute to PABPC1 binding, we tested whether GW182 mutants lacking either the M2 region or motif III interacted with PABPC1. We observed that these mutants interacted with PABPC1 more efficiently than did a GW182 mutant lacking the C-terminal region (Fig. 6B, lanes 16 and 17 versus lane 14) . These results suggest that the C-terminal region provides a major contribution to the interaction with PABPC1. PABPC1 binding was abolished when, in addition to the C-terminal region, motif III and the M2 region were deleted (Fig. 6D, lane 18) . To examine whether motif III and the M2 and C-terminal regions were also sufficient for PABPC1 binding, we tested fragments containing the entire silencing domain or the different regions in various combinations. We observed that a GW182 fragment containing motif III and the M2 and Cterminal regions was sufficient to interact with PABPC1 (Fig. 6D , lane 12 versus lane 9). Fragments lacking motif III interacted with PABPC1 although less efficiently, indicating that motif III contributes but is not absolutely required (Fig. 6D, lane 11) . We conclude that motif III together with the M2 and C-terminal regions defines the minimal PABPC1-binding domain in GW182." The silencing domain of GW182 interacts with PABPC1. (A and B) Lysates from S2 cells coexpressing GFP-tagged F-Luc, wild-type GW182, or GW182 mutants together with V5-tagged PABPC1 were immunoprecipitated using a polyclonal anti-GFP antibody. Inputs (4%) and immunoprecipitates (IP) (20%) were analyzed by Western blotting using anti-GFP and anti-V5 antibodies. In lanes 15 to 21 (A), cell lysates were treated with RNase A prior to immunoprecipitation. (C) Schematic diagram of the GW182 silencing domain. The middle region (M) consists of the M1 and M2 regions and motif III (also known as DUF) (33). C-term, C-terminal region; Dm, D. melanogaster. Amino acid positions at domain boundaries are indicated. (D) Lysates from S2 cells coexpressing GFP or GFP-tagged versions of wild-type GW182 or GW182 mutants together with V5-tagged PABPC1 were immunoprecipitated and analyzed as described above (A and B). 
Response to comments of Reviewer 1
Referee 1 recommends publication of our manuscript in the EMBO J. and requests that we address a minor comment.
1) The referee requests that we adjust the bar graph data in Figure 4 to reflect the relative concentration of the protein mutants shown in Figure 4H .
We agree with the referee that the proteins are not expressed at the same level. We quantified the Western blot signals in Figure 4H and found that wild-type GW182 expression is 3-fold lower than the expression of the inactive mutants. In fact, taken the protein levels into account strengthens our conclusions, because the mutants remain inactive even when they are expressed at levels higher than wild type. Nevertheless, we did not adjust the graph data to the protein concentrations because this would imply that the activity of the proteins is directly proportional to the protein concentration and this is not the case. Indeed, we observe the same silencing activity for the wild-type protein within a broad range of concentrations (between 10-100 ng of transfected plasmid, Supplementary Figures 2  and 3) . Similarly, the mutants remain inactive within this same range of concentrations ( Supplementary Figure 2) . Therefore, a 3-fold variation in protein concentration neither affects the functional assays nor the conclusions of Figure 4 . We have included a supplemental figure showing that the results of the complementation assay do not change when 10 to 100 ng of transfected plasmid are used ( Supplementary Figure 2) .
Response to comments of Reviewer 2
Reviewer 2 indicates that the manuscript could contribute to our understanding of the importance of the GW182-PABPC interaction. He/She requests that we address the following points.
1. The referee raises the question of the contribution of the GW182 M2, PAM2 motif and C-term regions to PABPC1-binding as deletion of the M2 region or the PAM2 motif alone has no effect.
We claim that these regions nevertheless contribute to PABPC1 binding because if they are deleted in combination with the C-term, then the affinity is lost. The referee requests that we show the effect of combining deletions of M2 and C-term, PAM2 and C-term, PAM2 and M2 to have a complete series of mutants.
We agree with the referee and performed the requested experiment, which is shown in a new version of Figure 2C . The Figure now includes all deletion mutants requested by the reviewer. Figure 2C shows that PABPC1-binding is not affected when the M2 region or the PAM2 motif are deleted individually (lanes 13 and 14). In contrast, deleting the C-term region reduces PABPC1binding (lane 15). PABPC1-binding decreases further when the C-term region is deleted in combination with the M2 region or the PAM2 motif (lanes 16 and 17). These results suggest the M2 region and the PAM2 motif contribute to PABPC1-binding, but their contribution becomes apparent only when binding to PABPC1 is impaired, for example by deleting the C-term region.
PABPC1 binding is abolished when all three regions are deleted (i.e. PAM2, M2 and C-term, lane 19). We also include a Supplementary Figure (S1) showing that the minimal fragment of GW182 that is sufficient for PABPC1 binding comprises the PAM2 motif and the M2 and C-term regions. In summary, we cannot ignore the contribution of the M2 and PAM2 motifs and claim that GW182-PABPC1 interaction is only mediated by the C-term region.
2. In this second comment, the referee again raises questions about the contribution of the PAM2 motif. This question is already addressed in point 1. Deletions or mutations of the PAM2 motif alone do not affect PABPC1 binding or silencing. However, as mentioned above, the PAM2 motif contributes to the affinity of the interaction, which is only revealed in the context of a protein that is already impaired in PABPC1-binding and silencing (for example a protein lacking the C-term). This explains why deleting the PAM2 motif exacerbates the effects of the C-term deletion. The silencing activity of the GW182 mutants in the complementation assay are fully consistent with the binding assay shown in Figure 2C . Indeed, a GW182 mutant lacking the PAM2 motif or the M2 region binds PABPC1 and is active, whereas a mutant lacking the C-term is impaired in PABPC1-binding and silencing. When all three regions are deleted PABPC1 binding is lost, as is the silencing activity.
Additional comments
1) The referee mentions that the sentence on page 18 is overstated:
"The differences between species in the requirements for PABPC1-binding can be attributed to the GW182 proteins and not to PABPC1 because human TNRC6s interact in a similar manner with both human and Dm PABPC1 (Figures 2 and 3) ." Because there are differences detected when comparing the binding ability of deleted M2 and C terminal TNRC6s mutants in insect S2 versus human Hek293 cells.
We think the referee is absolutely right and so deleted this sentence.
2) The referee thinks that Fig. 7 is not convincing and the claim that GW182 -PABPC interaction is required for silencing of unadenylated reporters is not supported by experimental evidence.
We disagree with the referee on this point. The data in Figure 7 fully supported our conclusion because it showed that a TNRC6B mutant that does not interact with PABPC1 could not rescue silencing of the unadenylated reporter. We do not think that PABPC1 is recruited to these mRNAs by GW182. In fact in experiments unrelated to this manuscript we detect PABPC1 bound to unadenylated reporters (independently of GW182). This is not surprising because PABPC1 establishes multiple interactions with translation factors including eIF4G, PAIP1 etc and not only with the poly(A) tail. Moreover, previous studies by the Sonenberg lab showed that PABPC1 can also stimulate translation of unadenylated transcripts, indicating that even in the absence of a poly(A) tail PABPC1 can be recruited to these RNAs.
We agree that the mechanism recruiting PABPC1 to these reporters is an unknown; however, it is not within the scope of this manuscript to determine how PABPC1 stimulates translation of unadenylated mRNAs. Moreover, the information in Figure 7 was not essential for the conclusions in the manuscript -unadenylated mRNAs are not natural miRNA targets-so we decided to delete this Figure. The meaning of the referee's last sentence was unclear to us. We are aware that PABPC1 interacts with many proteins, including EDD, but we are not using PABPC1 mutants. Our mutations are in the TNRC6 proteins and this should not interfere with the interactions of PABPC1 with its partners.
3) The referee mentions that the results shown in Fig. 8 can be indirect rendering the interpretation difficult. The referee suggests to remove these data and to provide more direct evidence to support the claim that the interaction of TNRC6s with PABPC1 contributes to silencing in human cells.
We fully agree with the referee on this point and have established a complementation assay in human cells. Using a combination of siRNAs targeting TNRC6A, B or C we found that the simultaneous knockdown of TNRC6A and TNRC6B inhibits miRNA-mediated silencing in HeLa cells. Silencing is restored by expressing an siRNA-resistant form of wild-type TNRC6A but not a mutant that does not interact with PABPC1. These data provides direct evidence for a role for the PABPC1-TNRC6 interaction in silencing in human cells.
Minor concern:
We agree with the referee and have revised the Figure legends. 2) Finally, the referee comments on a potential overlap with a previous manuscript by Zekri et al.
We feel this comment contradicts the comments on points 1 and 2. On points 1 and 2, the referee requests we repeat some of the experiments published by Zekri et al. because of questions about how much the M2 region contributes to PABPC1 binding.
In this manuscript, we paid special attention to point out that our results regarding GW182-PABPC1 interaction confirm those of Zekri et al. We extend those studies and carried out a side-byside comparison of GW182 and TNRC6B. We think it is important to show GW182 and TNRC6 experiments in parallel, although GW182 is in some of the experiments a positive but an important control to include.
2nd Editorial Decision 17 September 2010 I apologise for the delay in getting back to you with a decision on your revised manuscript, but I have been out of the office for the last couple of weeks and the review was only received yesterday. While the revised manuscript is improved, the one referee who has re-evaluated it requires that a number of clarifications are made. There is also the issue surrounding the previous work describing the interaction between GW182 and PABPC1, while the data should remain it is important that is is described in the correct context. Once these issues are satisfactorily addressed I would be happy to look through a revised version.
When you send us your revision, please include a cover letter with an itemised list of all changes made, or your rebuttal, in response to comments from review. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html
Thank you for the opportunity to consider your work for publication. I look forward to reading the revised manuscript.
Yours sincerely,
Editor
The EMBO Journal
The revision of "Two PABPC1-binding sites in GW182 proteins promote miRNA-mediated gene silencing" by Isauralade and co-workers addressed most of the concerns raised in the initial review of this work. In general this manuscript provides new information and deserves to be published. However, the manuscript is difficult to read. Many experiments not clearly described using many constructs which takes effort to deconvolute. Minimally, one few points needs to be addressed and a few minor issues still require clarification:
Major issue:
1. In the last lanes of Fig. 1C , ΔMLLE (the C-terminal portion of PABPC1) is shown to be required for interaction with GW182. The PABPC1 protein lacking the C terminal portion (ΔMLLE) does not co-precipitate TNRC6B (the human homolog of fly GW182). However, in the last lanes of Fig.  4E , RRM1-4-V5 (which is only the very N-terminal portion of PABPC1 and which lacks MLLE (ΔMLLE)) does co-precipitate TNRC6C. First, does RRM1-4-V5 co-precipitate TNRC6B?
2. If the message is that the MMLE motif is required for PABPC1 interaction with GW182 homologs, then Fig. 4E contradicts this conclusion.
3. Note that Fig. 1 deals with human proteins in fly extracts and Fig. 4 deals with human proteins in human extracts. Is there something about the nature of the different extracts that changes the interaction requirements between human proteins TNRC6B/6C and PABPC1? Have the authors done these experiments using only recombinant purified proteins not in extracts? Because all these experiments were performed by transfection followed by precipitation, it may be difficult to unequivocally determine the minimal requirements for the TNRC6B/6C-PABPC1 interaction.
The authors' thinking on this issue is not clear from their description:
On page 7, last paragraph, referring to Fig 1: "Together these results indicate that PABPC1 has two binding sites for GW182 proteins: one that is contributed by the RRM1 domain and another by the MLLE domain. The RRM1 domain is required for binding to Dm GW182 and only contributes to TNRC6B binding, whereas the MLLE domain is necessary for TNRC6B-binding."
On page 12 (top), referring to Fig. 4 : "These findings prompted us to test whether we could detect an interaction with the PABPC1 RRM1-4 domains in human cells. Consistent with our analysis in S2 cells, the TNRC6C silencing domain interacted with PABPC1 fragments containing either the RRM1-4 or RRM1-2 domains (Fig.  4E lanes 10 and 12) ."
Based on results presented in Fig.1E and 4E , MLLE domain of PABPC1 appears dispensable for TNRC6 protein binding. The minimum interacting domains are RRM1-2 in PABPC1 and the silencing domain in TNRC6s. The authors should comment on the difference observed in S2 cells, (Fig 1C lane 28) where the deletion of MLLE domain of PABC prevents interaction with TNRC6B.
Related to the points above, in Fig. 8 the authors demonstrate that only TNRC6A and TNRC6B are important for silencing in human cells. They knocked down TNRC6A and TNRC6B genes (presumably leaving TNRC6C intact) which de-repressed silencing. This data suggests that the TNRC6C interaction with PABPC1 studied in Fig. 4 is non-functional because TNRC6C is still present in the knockdown extract. Also, the data in Fig. 8B is ambiguous which demonstrates overexpression of a mutant form of TNRC6C which presumably blocks endogenous TNRC6C activity.
This point wasn't demonstrated so this figure is hard to interpret.
Because the TNRC6C interaction with PABPC1 is not required for silencing the authors should clearly state this conclusion. Their conclusion (last line of p. 16) " Altogether, these data support the idea that the interaction of TNRC6s with PABPC1 is also critical for silencing miRNA targets in human cells" is not completely accurate. A more accurate statement based on the data is that the TNRC6A interaction with PABPC1 is important.
Minor issues requiring clarification:
1. Many deletions and truncations of PABPC1 protein are used throughout this study. It would be helpful for the general reader to include a schematic representation showing the domain structure of PABPC1 in addition to the schematic presented for TNRC6B and GW182 (Fig. 1A) .
2. Two figures/legends require additional information.
2.1 Annotation of Fig. 1E : Were the untagged or the V5-tagged PABC1 and -truncations detected by Western blotting? If there is no tag, how did the authors precipitate these fragments and/or how did they detect these fragments in Western blots? 2.2 What is "delta M" in Fig. 4D ? This is not represented clearly in Fig. 1A schematics.
Other issue of Note:
The authors appear to have misinterpreted our concern regarding previously published results. While we do understand the importance of comparing side by side the interactions established between PABPC1 -GW182 and PABPC1-TNRC6 homologs, we maintain our original issue that some of the findings presented in Seven out of ten constructs used in Huntzinger Fig. 2C were analyzed by Zekri Fig. 6B , and Huntzinger Fig. 2C leads to the same conclusions as Zekri. Lanes 11, 12, 13, 14, 15, 19 and 20 of Huntzinger Fig. 2C are identical to lanes 10,11,16 ,17,14,18 and 15 respectively, from Zekri Fig. 6B . The only difference is the nomenclature. The PAM2 domain from Huntzinger is called domain III in Zekri.
As we mentioned in our original review, very similar observations and interpretations were published in Zekri, page 6225 last paragraph and page 6228, first paragraph: "...To define which sequences within the middle region contribute to PABPC1 binding, we tested whether GW182 mutants lacking either the M2 region or motif III interacted with PABPC1. We observed that these mutants interacted with PABPC1 more efficiently than did a GW182 mutant lacking the C-terminal region (Fig. 6B, lanes 16 and 17 versus lane 14) . These results suggest that the C terminal region provides a major contribution to the interaction with PABPC1. PABPC1 binding was abolished when, in addition to the C-terminal region, motif III and the M2 region were deleted (Fig. 6D, lane 18) .
To examine whether motif III and the M2 and C-terminal regions were also sufficient for PABPC1 binding, we tested fragments containing the entire silencing domain or the different regions in various combinations. We observed that a GW182 fragment containing motif III and the M2 and C terminal regions was sufficient to interact with PABPC1 (Fig.6D, lane 12 versus lane 9) . Fragments lacking motif III interacted with PABPC1 although less efficiently, indicating that motif III contributes but is not absolutely required (Fig. 6D, lane 11) . We conclude that motif III together with the M2 and C-terminal regions defines the minimal PABPC1-binding domain in GW182."
In Huntzinger (p. 8), last paragraph: " In the context of full length Dm GW182, deleting the PAM2 motif has little to no effect (Fig. 2C,  lane 11) ; however, PABPC1 will not bind to Dm GW182 if in addition to the PAM2 motif, the M2 and C-term regions are deleted ( Figure 2C, lane 15) . A similar effect is observed when the entire silencing domain is deleted (Figure2C, lane 16; and Zekri et al, 2009 ). An important implication of these results is that, in addition to the M2 and C-term regions, the PAM2 motif of GW182 contributes to PABPC1-binding, although on its own this motif is not sufficient."
This statement in Huntzinger is misleadingly restated as a novel observation. We again request that the authors clearly indicate what was previously known and what is the novel information gained from the present study.
We disagree with author's statement implying contradiction in our requests. By addressing points 1 and 2 of our critique, the authors were not asked to repeat previously published experiments by Zekri but instead to generate new data not previously published by Zekri.
In conclusion, this manuscript contains new data that deserves to be published. This manuscript does not depend upon observations contained in Fig. 2C . We recommend that this data be removed from Huntzinger because it is a repetition of previously published work. However, we defer to the Editor's discretion what are new observations. Response to comments of Reviewer 2
Major issues
1. The referee writes that "In the last lanes of Fig. 1C , the MLLE (the C-terminal portion of PABPC1) is shown to be required for interaction with GW182". This statement is incorrect; Figure   1C shows the interaction of TNRC6B (not of GW182) with PABPC1. We believe that the Figure is clearly labelled.
Also, the answer to the referee's question of whether RRM1-4 co-precipitates TNRC6B was already in the paper and shown in Figure 1E . Figure 1E clearly shows that TNRC6B interacts with PABPC1 fragments containing RRM1-4 (lane 15) and also with the MLLE domain (lane 18).
Note that the experiments shown in Figure 4 cannot be compared with the experiments in Figure 1 because in these figures we investigate the interaction of the TNRC6 proteins with human PABPC1 in human cells, and with Drosophila PABPC1 in Drosophila cells, respectively.
2. PABPC1 provides two binding sites for GW182 proteins: one within the N-terminal RRM domains and one at the MLLE domain. Figure 4E therefore does not contradict our conclusions;
both fragments bind TNRC6B, not one or the other as assumed by the referee. Figure 1 and Figure 4 is that in Figure 1 we investigate the interaction of human proteins with Drosophila PABPC in Drosophila cells,
The main difference between the experiments shown in
whereas in Figure 4 we analyze the interaction of human proteins with human PABPC1 in human cells. It is therefore to be expected that some differences are observed. Indeed, the main focus of the manuscript is to investigate species-specific differences in the interaction between GW182 proteins and PABPC1 in Drosophila and human cells. These differences are not due to the nature of the extracts but, as shown in this manuscript, can be attributed to sequence differences between these species with respect to both the PABPC1 proteins and the GW182/TNRC6 proteins.
The referee requested that we confirm the interactions described in this manuscript using recombinant proteins expressed in E. coli. We agree with the referee and have performed GST pull-down assays using recombinant proteins expressed in bacteria. These experiments confirm the results obtained from co-immunoprecipitation assays.
First, using recombinant proteins we show that the PAM2 motifs of human TNRC6B and Drosophila GW182 mediate direct PABPC1 binding. In contrast, the M2 and C-term regions contribute to PABPC1 binding only in vivo, indicating the interaction of the M2 and C-term regions with the RRM domains of PABPC1 is indirect and mediated by additional proteins present in cell lysates. These experiments are now shown in Figures 4E and 5 . The original Figure 4E has been deleted because the results from the pull-down assays make this information redundant.
Finally, we confirmed that the interactions described in this manuscript are not RNA-mediated because they are also observed in cell lysates treated with micrococcal nuclease.
Other issues:
1. Page 7. The statement on Page 7 has been deleted in the new version of the manuscript because this point has been addressed in several other paragraphs as well as in the conclusions from the GST pull-down assays.
2. Page 12. As mentioned above, the main conclusion of this manuscript is that PABPC1 provides two binding sites for GW182 proteins: one at the N-terminal RRM domains and one at the MLLE domain. In vivo, both fragments bind TNRC6B; it is not a case of either one or the other.
Therefore, although we observe binding with each fragment individually, this binding is less efficient than that observed with full length PABPC1. Therefore we conclude that the RRM domains and the MLLE domain contribute (either additively or synergistically) to the interaction of PABPC1 with GW182 proteins. The differences between human and Drosophila cells are extensively discussed in the Discussion.
3. Response to referee's comment on Figure 8 (in the revised manuscript this figure is Figure 9 ).
We believe that the referee misinterprets the results from the RNAi knockdowns in human cells. It is well established that negative results in RNAi experiments cannot be interpreted. Therefore, there is no experimental evidence in this manuscript to support the referee's statement that "TNRC6C interaction with PABPC1 is non-functional". As described in the manuscript, we initially depleted TNRC6 proteins using a combination of different siRNAs (2 siRNAs per protein) and obtained the best suppression of silencing when we co-depleted TNRC6A and TNRC6B. We therefore performed the experiments using these siRNAs. We did not investigate why the siRNAs targeting TNRC6C are less efficient, and therefore we cannot draw any conclusion about TNRC6C activity. Clearly, co-depleting TNRC6A and TNRC6B suppresses silencing in HeLa cells, although reporter expression is not fully restored (compare Figures 9C and 9D ), suggesting either that there are residual amounts of TNRC6A and/or B, or that TNRC6C is active in these cells.
Furthermore, the relative expression levels of the TNRC6 proteins in our HeLa cell line are not known, and it could be that TNRC6C is expressed at very low levels in these cells.
The referee also misinterprets the results shown in Figure 8B (now Figure 9B ). This Figure shows that overexpression of wild-type TNRC6C stimulates silencing, suggesting that the TNRC6 proteins may be limiting for silencing in HeLa cells. In contrast, a mutant that does not interact with PABPC1 cannot stimulate silencing. It is unclear why the referee thinks that we block TNRC6C activity. The overexpressed proteins have no dominant negative effects; they stimulate silencing or have no effect. We would also like to point out that TNRC6A, B, and C are redundant and, to date, there is no evidence of functional differences between these proteins.
4. As mentioned above the referee over-interprets our results and the statement "Because the TNRC6C interaction with PABPC1 is not required for silencing..." is not warranted. There is no evidence in this manuscript supporting such a statement.
Minor issues:
1. We have included a diagram of PABPC1 domain organization in Figure 1A .
2.1 We have changed the annotation of Figure 1E to show that the proteins have a V5 tag. Figure 1A .
We now show the M fragment in
Finally, to make the manuscript more accessible we have now included a cartoon summarizing the interactions described in this study ( Figure 9F ).
As mentioned in our previous response, we are fully aware of our previous observations and in this manuscript we have paid special attention to point out that some of the results regarding the GW182-PABPC1 interaction confirm those of Zekri et al. We have extended those studies and carried out a side-by-side comparison of GW182 and TNRC6B. We still think it is important to show GW182 and TNRC6 experiments in parallel, although in some of the experiments GW182 is included as a positive but an important control. We have once again checked the description of Figure 2C and ensured that we refer to the Zekri et al. paper whenever the results are confirmatory of that paper.
We have changed the name of the DUF domain to take into account recently published biochemical and structural evidence showing that the sequence previously known as the DUF domain (or motif III) is in fact a PAM2 motif. The term DUF domain was inappropriate because this short sequence is not a domain but a motif.
3rd Editorial Decision 12 October 2010
Thank you for submitting a revised version of your manuscript, I have read through your response to the remaining concerns of referee #2 and find that the study can be accepted for publication in The EMBO Journal. You will receive the official acceptance letter in the next day or so.
Sincerely yours,
Editor EMBO Journal
